A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair Loss
In the register
The register attaches this trial to Upadacitinib (Rinvoq) (AbbVie), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Active, not recruiting
- Declared phase
- Phase 3
- Sponsor
- AbbVie
- Participants (registry)
- 125
- Start
- June 2025
- Primary completion
- February 2029 (planned)
- Study completion
- February 2029 (planned)
- Last registry update
- July 2026
- Countries
- Japan
Conditions studied: Alopecia Areata
Interventions: Upadacitinib, Upadacitinib Placebo
Other trials of Upadacitinib (Rinvoq)
- NCT04159597Available (expanded access)
Expanded Access to Upadacitinib
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.